Literature DB >> 15848587

Posttransplant lymphoproliferative disorder: significance of central nervous system involvement.

J F Buell1, T G Gross, M J Hanaway, J Trofe, P Roy-Chaudhury, M R First, E S Woodle.   

Abstract

BACKGROUND: Few data exist regarding central nervous system (CNS) involvement in patients with posttransplant lymphoproliferative disorder (PTLD). The purpose of this study was to review the Israel Penn International Transplant Tumor Registry (IPITTR) experience with CNS involvement by PTLD.
METHODS: Nine hundred ten PTLD cases from the United States were reported to the IPITTR and reviewed for CNS involvement.
RESULTS: One hundred thirty-six transplant recipients with PTLD (15%) had CNS involvement. The highest incidence of CNS involvement occurred in pancreas (3 of 11; 27%) and kidney transplant recipients (76 of 429; 18%). Fifteen cases occurred in children and 121 cases in adults. For both children and adults, isolated CNS disease was associated with better survival when compared with multiple-site involvement (children: 29% vs 0%; adults: 12% vs 6%; P < .05). Three-year survival in PTLD patients with CNS involvement was 9.4% and without CNS involvement was 49.4% (P < .01). Radiation therapy alone appeared to provide the best survival rates (25%).
CONCLUSIONS: CNS involvement in transplant recipients with PTLD carries an ominous prognosis; however, isolated CNS involvement has a better prognosis than CNS plus extracranial involvement. Radiation therapy alone provides the best results, but this may be a reflection of isolated CNS disease.

Entities:  

Mesh:

Year:  2005        PMID: 15848587     DOI: 10.1016/j.transproceed.2004.12.130

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  27 in total

1.  Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.

Authors:  M Wu; J Sun; Y Zhang; F Huang; H Zhou; Z Fan; L Xuan; G Yu; X Guo; M Dai; R Feng; Q Liu
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

2.  High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.

Authors:  A Patrick; A Wee; A Hedderman; D Wilson; J Weiss; M Govani
Journal:  J Neurooncol       Date:  2010-09-26       Impact factor: 4.130

Review 3.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

Review 4.  Post Transplant Lymphoproliferative Disorder.

Authors:  Devika Gupta; Satish Mendonca; Sushmita Chakraborty; Tathagata Chatterjee
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-17       Impact factor: 0.900

Review 5.  Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Authors:  Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 6.  Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?

Authors:  Daan Dierickx; Nina Cardinaels
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

7.  Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

Authors:  Robert Cavaliere; Gina Petroni; Maria B Lopes; David Schiff
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

8.  EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases.

Authors:  J Sanz; M Arango; L Senent; I Jarque; P Montesinos; A Sempere; I Lorenzo; G Martín; F Moscardó; E Mayordomo; M Salavert; C Cañigral; B Boluda; C Salazar; J L López-Hontangas; M A Sanz; G F Sanz
Journal:  Bone Marrow Transplant       Date:  2013-12-02       Impact factor: 5.483

9.  Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.

Authors:  T G Gross; M A Orjuela; S L Perkins; J R Park; J C Lynch; M S Cairo; L M Smith; R J Hayashi
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

Review 10.  Post-transplant lymphoproliferative disorder in the pelvis successfully treated with consolidative radiotherapy.

Authors:  Omar Habibeh; Khaled Elsayad; Jan Kriz; Uwe Haverkamp; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2016-06-22       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.